Download pdf
New progress in cancer treatment based on monoclonal antibodies
- 1 RCF experimental school, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
Monoclonal antibodies (mAbs) have emerged as a promising approach in cancer treatment, offering high specificity, fewer adverse reactions, and improved prognoses compared to traditional chemotherapy and radiotherapy. These drugs utilize monoclonal antibodies to precisely target and bind to cancer-specific markers, enhancing treatment efficacy. Since the approval of the first monoclonal antibody drug in 1986, the field has expanded significantly, with thousands of such drugs now available globally. In China, 53 mAbs have been approved as of 2021. Despite these advances, challenges such as drug resistance and high costs remain. However, continued scientific research and technological innovation are expected to address these issues and further improve treatment outcomes. The integration of individualized treatment plans, tailored to the specific characteristics of patients' tumors, holds the potential to revolutionize cancer care. With ongoing clinical trials and research, mAbs are expected to play an increasingly vital role in cancer therapy, offering new hope to patients and contributing to the global fight against this life-threatening disease.
Keywords
Cancer therapy, monoclonal antibodies, drug resistance
[1]. Qin, Y., Pan, M., & Zhang, J. (2024). Application and progress of antibody drugs in cancer treatment. Progress in Pharmaceutical Sciences, 48(01), 6-19.
[2]. Lu, M., Song, H., & Xiao, S. (2024). Occurrence of cancer and targeted therapy. World Science, (06), 28-32.
[3]. Fu, Y., Li, S., Jiang, H., et al. (2024). Mechanism and preclinical evaluation of monoclonal antibody-induced cytokine release syndrome. Chinese Journal of New Drugs, 33(14), 1442-1448.
[4]. Mckertish, C. M., & Kayser, V. (2021). Advances and limitations of antibody-drug conjugates for cancer. Biomedicines, 9(8), 872.
[5]. Banday, A. H., & Abdalla, M. (2023). Immune checkpoint inhibitors: Recent clinical advances and future prospects. Current Medicinal Chemistry, 30(28), 3215-3237.
[6]. Zahavi, D., & Weiner, L. (2020). Monoclonal antibodies in cancer therapy. Antibodies, 9(3), 34.
[7]. Yu, Y., Yan, L., & Liu, B. (2021). Mechanism and research progress of anti-CD38 monoclonal antibody in the treatment of multiple myeloma. Chinese Journal of Immunology, 37(18), 2300-2306.
[8]. Kinch, M. S., Kraft, Z., & Schwartz, T. (2023). Monoclonal antibodies: Trends in therapeutic success and commercial focus. Drug Discovery Today, 28(1), 103415.
[9]. Wang, G., Li, B., Ren, R., et al. (2024). Clinical application recommendations for anti-Aβ monoclonal antibodies (2024 edition). Chinese Journal of Modern Neurological Diseases, 24(03), 120-126.
[10]. Gao, Q. (2021). Protective effects and mechanisms of MMP-9 monoclonal antibody L13 on blood-brain barrier after acute stroke. Zhengzhou University (Master's thesis).
Cite this article
Zhao,Z. (2024). New progress in cancer treatment based on monoclonal antibodies. Theoretical and Natural Science,70,33-37.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).